| Company | Value | Change | %Change |
|---|
Navin Fluorine’s revenue was in-line with estimates, while its net profit and EBITDA margin exceeded estimates for the quarter. The management said that they expect strong growth in the CDMO business in FY26.
Global brokerage firm UBS has increased its price target on Navin Fluorine to ₹4,850. The brokerage has also maintained its ‘Buy’ recommendation on the stock.
The revised price target from UBS implies a potential upside of 24% from Thursday’s closing levels. This is also the highest price target for the stock on the Street.UBS said that Navin Fluorine’s Q3 earnings beat consensus on growth and profitability. Revenue and EBITDA increased by 21% and 95% year-on-year, respectively, with margins at 24.3%.
Meanwhile, Jefferies has upgraded Navin Fluorine to ‘Buy’ from ‘Underperform,’ raising its price target to ₹4,600 per share from ₹3,090 earlier.
The brokerage said that the company is entering a phase of high growth after experiencing significant earnings cuts over the last five quarters.Despite a challenging demand environment, Navin Fluorine has managed to sign up new contracts.
Jefferies has also upgraded its FY26 and FY27 earnings per share estimates by 11% and 13%, respectively, and projected a 30% EPS CAGR over FY25-27.
Citi, too, has increased its price target for Navin Fluorine to ₹4,500 per share. The brokerage has recommended a ‘Buy’ rating on the stock.
On the charts, Navin Fluorine’s relative strength index (RSI) is nearing levels of 70, currently at 63.8. An RSI reading above 70 indicates that the stock is in overbought territory.
Out of the 29 analysts that have coverage on Navin Fluorine, 22 of them have a ‘Buy’ recommendation, three of them say ‘Hold’, while four have a ‘Sell’ rating on the stock.
Shares of Navin Fluorine International Limited are trading 8.73% higher on Friday at ₹4,249.30 and the stock is trading at its 52-week high of ₹4,299.05.
